In conclusion, our results define in CML a pathogenetic pathway in which the aberrant expression and activation of Aurora kinase A initiates MDM2‐mediated ubiquitination of SETD2, as previously described in advanced systemic mastocytosis.25 This evidence concerns the gene SETD2 and chronic myelogenous leukemia, BCR-ABL1 positive.